# Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

> **NCT01515657** · PHASE3 · COMPLETED · sponsor: **PLx Pharma** · enrollment: 40 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** PL2200 Aspirin Capsules
- **DRUG:** Immediate-Release Aspirin Tablets
- **DRUG:** Enteric-coated aspirin caplets

## Key facts

- **NCT ID:** NCT01515657
- **Lead sponsor:** PLx Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01515657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01515657, "Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01515657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*